135 related articles for article (PubMed ID: 25981606)
1. Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
Pirozzi L; Sountoulides P; Castellan P; Presicce F; Lombardo R; Romero M; De Nunzio C; Tubaro A; Schips L; Cindolo L
Curr Drug Targets; 2015; 16(11):1165-71. PubMed ID: 25981606
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia.
Zong HT; Peng XX; Yang CC; Zhang Y
Asian J Androl; 2011 Nov; 13(6):812-8. PubMed ID: 21892196
[TBL] [Abstract][Full Text] [Related]
3. Future aspects of plant derived bioactive metabolites as therapeutics to combat benign prostatic hyperplasia.
Krishnamoorthi R; Ganapathy A A; Hari Priya VM; Kumaran A
J Ethnopharmacol; 2024 Aug; 330():118207. PubMed ID: 38636573
[TBL] [Abstract][Full Text] [Related]
4. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.
Parsons JK; Schenk JM; Arnold KB; Messer K; Till C; Thompson IM; Kristal AR; ;
Eur Urol; 2012 Aug; 62(2):234-41. PubMed ID: 22459892
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Finasteride and Dutasteride on Risk of Prostate Cancer in Patients with Benign Prostatic Hyperplasia: A Pooled Analysis of 15 Real-world Databases.
Yang DY; Seo WW; Park RW; Rhee SY; Cha JM; Hah YS; Jeong CW; Kim KJ; Yang HJ; Kim DK; Ha JY
World J Mens Health; 2024 May; ():. PubMed ID: 38772542
[TBL] [Abstract][Full Text] [Related]
6. Does treatment with dutasteride or finasteride has impact on renal morphology? Experimental study.
Silva MHAD; Estrada JHD; Gregório BM; Sampaio FJB; Souza DB
Acta Cir Bras; 2021; 36(7):e360703. PubMed ID: 34550196
[TBL] [Abstract][Full Text] [Related]
7. The post-finasteride syndrome: possible etiological mechanisms and symptoms.
Leliefeld HHJ; Debruyne FMJ; Reisman Y
Int J Impot Res; 2023 Sep; ():. PubMed ID: 37697052
[TBL] [Abstract][Full Text] [Related]
8. Comparisons of the Efficacy and Safety of Finasteride and Dutasteride for Benign Prostatic Hyperplasia: A Network Meta-Analysis.
Yin T; Qiao Z; Li Y; Li D; Jiang M; An C; Wang F; Zuo M; Hu K; Li Q
Am J Ther; 2017; 24(5):e517-e523. PubMed ID: 26322675
[TBL] [Abstract][Full Text] [Related]
9. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.
Wang XH; Wang X; Shi MJ; Li S; Liu T; Zhang XH
Asian J Androl; 2015; 17(6):1022-32. PubMed ID: 25994648
[TBL] [Abstract][Full Text] [Related]
11. Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia.
Traish AM; Haider KS; Doros G; Haider A
Horm Mol Biol Clin Investig; 2015 Sep; 23(3):85-96. PubMed ID: 26053014
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia--The Markov model based on data from Montenegro.
Dabanović V; Kostić M; Janković S
Vojnosanit Pregl; 2016 Jan; 73(1):26-33. PubMed ID: 26964381
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized and comparative study in Chinese patients.
Hu R; Xu F; Sheng Y; Qi S; Han Y; Miao Y; Rui W; Yang Q
Dermatol Ther; 2015; 28(5):303-8. PubMed ID: 26031764
[TBL] [Abstract][Full Text] [Related]
14. Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia?
Alcántara-Montero A; Brenes-Bermúdez FJ
Actas Urol Esp; 2016 May; 40(4):268-9. PubMed ID: 26774534
[No Abstract] [Full Text] [Related]
15. Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis.
Yuan JQ; Mao C; Wong SY; Yang ZY; Fu XH; Dai XY; Tang JL
Medicine (Baltimore); 2015 Jul; 94(27):e974. PubMed ID: 26166130
[TBL] [Abstract][Full Text] [Related]
16. Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials.
Zhu YP; Dai B; Zhang HL; Shi GH; Ye DW
BMC Urol; 2015 Jun; 15():47. PubMed ID: 26032962
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of 5α-reductase inhibitors for patients with large benign prostatic hyperplasia (>80 mL) after transurethral resection of the prostate.
Qian X; Yu G; Qian Y; Xu D; Liu H; Kong X; Zhu Y; Wang Z; Zheng J; Qi J
Aging Male; 2015; 18(4):238-43. PubMed ID: 26225794
[TBL] [Abstract][Full Text] [Related]
18. Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study.
Wada N; Hashizume K; Matsumoto S; Kakizaki H
Aging Male; 2016; 19(1):12-4. PubMed ID: 26225793
[TBL] [Abstract][Full Text] [Related]
19. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014).
Oelke M; Becher K; Castro-Diaz D; Chartier-Kastler E; Kirby M; Wagg A; Wehling M
Age Ageing; 2015 Sep; 44(5):745-55. PubMed ID: 26104505
[TBL] [Abstract][Full Text] [Related]
20. Caution is recommended prior to sildenafil use in vascular anomalies.
Rankin H; Zwicker K; Trenor CC
Pediatr Blood Cancer; 2015 Nov; 62(11):2015-7. PubMed ID: 25982365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
